华东医药(000963.SZ)：注射用HDM2005药品临床试验申请获得美国FDA批准

智通财经07-01

智通财经APP讯，华东医药(000963.SZ)发布公告，近日，公司全资子公司杭州中美华东制药有限公司(“中美华东”)收到美国食品药品监督管理局(“美国FDA”)通知，由中美华东申报的注射用HDM2005药品临床试验申请已获得美国FDA批准，可在美国开展I期临床试验。据悉，ROR1是一种典型的肿瘤胚胎蛋白，具有肿瘤细胞特异性，在多种实体瘤和血液瘤中高表达，是潜力ADC靶点。ADC兼具抗体分子高度...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2448693079?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-01 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2448693079","market":"sh","top_or_hot":-1,"title":"华东医药(000963.SZ)：注射用HDM2005药品临床试验申请获得美国FDA批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，华东医药(000963.SZ)发布公告，近日，公司全资子公司杭州中美华东制药有限公司(“中美华东”)收到美国食品药品监督管理局(“美国FDA”)通知，由中美华东申报的注射用HDM2005药品临床试验申请已获得美国FDA批准，可在美国开展I期临床试验。据悉，ROR1是一种典型的肿瘤胚胎蛋白，具有肿瘤细胞特异性，在多种实体瘤和血液瘤中高表达，是潜力ADC靶点。ADC兼具抗体分子高度...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1143597.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>华东医药(000963.SZ)：注射用HDM2005药品临床试验申请获得美国FDA批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n华东医药(000963.SZ)：注射用HDM2005药品临床试验申请获得美国FDA批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-01 17:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1143597.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，华东医药(000963.SZ)发布公告，近日，公司全资子公司杭州中美华东制药有限公司(“中美华东”)收到美国食品药品监督管理局(“美国FDA”)通知，由中美华东申报的注射用HDM2005药品临床试验申请已获得美国FDA批准，可在美国开展I期临床试验。据悉，ROR1是一种典型的肿瘤胚胎蛋白，具有肿瘤细胞特异性，在多种实体瘤和血液瘤中高表达，是潜力ADC靶点。ADC兼具抗体分子高度...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1143597.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1576","symbol_name":"医药外包概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1143597.html","article_id":"2448693079","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2448693079","pubTimestamp":1719824676,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，华东医药 发布公告，近日，公司全资子公司杭州中美华东制药有限公司收到美国食品药品监督管理局通知，由中美华东申报的注射用HDM2005药品临床试验申请已获得美国FDA批准，可在美国开展I期临床试验。HDM2005已经在临床前研究、药代动力学研究及安全性评价中展现出良好的抗肿瘤活性和安全性。本次注射用HDM2005临床试验获批，是该款产品研发进程中的重要里程碑，将进一步提升公司在ADC肿瘤治疗领域的核心竞争力。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1576":"医药外包概念","BK0175":"白马股","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0188":"融资融券","BK1583":"高瓴概念","03347":"泰格医药","BK0187":"一线龙头","BK0183":"MSCI概念","BK0132":"高送转概念","BK0196":"行业龙头","000963":"华东医药","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0209":"零售","BK1141":"生命科学工具和服务"},"translate_title":"Huadong Medicine (000963. SZ): The clinical trial application of HDM2005 drug for injection has been approved by the US FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000963":1,"03347":1},"content_text":"智通财经APP讯，华东医药(000963.SZ)发布公告，近日，公司全资子公司杭州中美华东制药有限公司(“中美华东”)收到美国食品药品监督管理局(“美国FDA”)通知，由中美华东申报的注射用HDM2005药品临床试验申请已获得美国FDA批准，可在美国开展I期临床试验。据悉，ROR1是一种典型的肿瘤胚胎蛋白，具有肿瘤细胞特异性，在多种实体瘤和血液瘤中高表达，是潜力ADC靶点。ADC兼具抗体分子高度靶向性和细胞毒素强大杀伤力的特点。HDM2005已经在临床前研究、药代动力学研究及安全性评价中展现出良好的抗肿瘤活性和安全性。本次注射用HDM2005临床试验获批，是该款产品研发进程中的重要里程碑，将进一步提升公司在ADC肿瘤治疗领域的核心竞争力。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2448693079"}